Interesting facts
Interesting Facts about 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
This compound displays intriguing characteristics that make it a noteworthy subject of study in the field of medicinal chemistry. Known for its potential as a therapeutic agent, it incorporates several unique structural components that contribute to its biological activity. Here are some fascinating aspects:
- Complex Structure: The compound contains a 4-methylpiperazine moiety, a feature that is often associated with enhanced solubility and bioavailability in drug design.
- Diverse Biological Targets: Its structure suggests activity against various enzymatic targets, particularly related to cancer therapies, due to its multi-ring framework and the presence of the pyrimidine derivative.
- Research Potential: Studies focusing on similar compounds have indicated promising results in inhibiting specific pathways involved in tumor growth, making this compound a candidate for future development and testing.
- Drug Development Insights: Understanding the interaction of this compound with biological receptors is essential for the advancement of pharmacological therapies. It exemplifies how synthetic modifications can influence biological behavior significantly.
As a testament to its complexity and potential, compounds like this are crucial in the continual search for new medications. They highlight the importance of molecular architecture in designing effective anti-cancer agents, revealing how small changes in chemical structure can lead to significant variations in pharmacological effects. The journey from synthesis to application is filled with exciting challenges and discoveries!
Synonyms
Imatinib
152459-95-5
STI571
Imatinib (STI571)
sti-571
Imatinib free base
Glamox
Cgp 57148
N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
STI 571
CCRIS 9076
UNII-BKJ8M8G5HI
BKJ8M8G5HI
Imatinib (INN)
NSC-743414
NSC-759854
4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
CHEBI:45783
CGP-57148
152459-95-5 (free base)
MFCD05662257
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
CHEMBL941
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
DTXSID3037125
NSC743414
NSC 743414
NSC 759854
4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide
Benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-
N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide
IMATINIB [INN]
Imatinib [INN:BAN]
alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide
4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
STI
BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-
Glamox (TN)
SR-01000763561
NCGC00159456-02
ST1571
ST 1571
Imatinibum
Imatinib base
imatinib-CD3
1iep
1xbb
Gleevec(TM)
4-((4-Methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)benzamide
4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)phenyl)benzamide
4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-(4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL)-BENZAMIDE
4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide; CGP 57148; Genfatinib; Imatinib, Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
4-[(4-methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl)-benzamide
4-[(4-methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide
Imatinib (Gleevec)
Imatinib, 21
Imatinib (Standard)
Imatinib, Free base
Kinome_3724
112GI019
IMATINIB [MI]
IMATINIB [VANDF]
IMATINIB [WHO-DD]
Gleevec (TN) (Novartis)
cid_5291
SCHEMBL3827
IMATINIB [EMA EPAR]
STI-571; IMATINIB
BIDD:GT0047
GTPL5687
DTXCID1017125
BDBM13530
EX-A063
L01XE01
BCPP000205
HMS2089D03
HMS3244P06
HMS3244P10
HMS3244P14
HMS3656K04
HMS3715P03
Imatinib base - Bio-X trade mark
Pharmakon1600-01502276
BCP01542
AC-524
HY-15463R
NSC759854
NSC800772
STK617705
AKOS000280662
BCP9000775
CCG-101289
CS-0964
DB00619
ES-0058
FM10813
NSC-800772
PA-5291
SB17306
SDCCGSBI-0634386.P009
MRF-0000449
NCGC00159456-01
NCGC00159456-03
NCGC00159456-04
NCGC00159456-05
NCGC00159456-06
NCGC00159456-07
NCGC00159456-09
NCGC00159456-16
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate
BI164570
HY-15463
N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
SY028029
I0906
NS00009172
S2475
SW197805-5
D08066
EN300-123057
AB00698388-07
AB00698388-10
AB00698388-11
AB00698388-12
AB00698388-13
AB00698388_15
AB00698388_16
Q177094
SR-01000763561-4
SR-01000763561-6
BRD-K92723993-001-06-7
BRD-K92723993-001-12-5
BRD-K92723993-066-02-9
BRD-K92723993-066-04-5
BRD-K92723993-066-22-7
Z1546624232
1080014-82-9
4-(4-Me-piperazin-1-ylmethyl)-N-[4-Me-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
4-(4-Methylpiperazin-1-yl)methyl-N-4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenylbenzamide
4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide
4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide
4-[(4-methyl-1-piperazinyl)methyl]-n[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide
benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)
N-[4-Methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]benzamide
Solubility of 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide
The solubility of this compound, known by its lengthy IUPAC name, is a critical aspect that influences its application in various chemical processes and pharmaceuticals. Here are some key points regarding its solubility:
In conclusion, while the solubility profile of 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide may not be straightforward, understanding these factors is essential for its effective use in applications. As the adage goes, “solubility is often the key to the bioavailability of a substance.”